Overview: Angiotensin-Converting Enzyme TestIntroduction: The Angiotensin-Converting Enzyme (ACE) Test measures ACE levels to diagnose sarcoidosis or other conditions causing lung issues, fatigue, or skin rashes. Following 2023 ATS guidelines, it uses spectrophotometry for high accuracy, aiding in metabolic screening. This test is critical for guiding treatment, monitoring disease activity, and improving outcomes in biochemistry for patients with suspected sarcoidosis.
Other Names: ACE Assay, Serum ACE Test.
FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for diagnostic accuracy.
Historical Milestone: ACE testing began in the 1970s for sarcoidosis. Spectrophotometric assays emerged in the 1980s, and by the 2000s, high-sensitivity methods improved diagnostic precision.
Purpose: Diagnoses sarcoidosis, guides treatment, and monitors disease activity in patients with lung issues, fatigue, or skin rashes.
Test Parameters: 1. Angiotensin Converting Enzyme
Pretest Condition: Fasting for 10-12 hours required to stabilize enzyme levels. Collect serum, plasma, or CSF after overnight fasting. Report symptoms like fatigue or rashes, and list medications like ACE inhibitors.
Specimen: 2-5 mL serum (SST), 2-4 mL plasma (EDTA), or 1-2 mL CSF (sterile container). Centrifuge serum or plasma within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document sarcoidosis symptoms, lung issues, or family history of granulomatous diseases. Include current medications, especially ACE inhibitors.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for imaging or treatment.
Procedural Considerations: Uses spectrophotometry to measure ACE levels. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: ACE inhibitors or non-fasting samples may alter results. Hemolysis or improper storage can degrade samples.
Clinical Significance: Elevated ACE levels suggest sarcoidosis, prompting imaging or treatment. Normal levels may require further testing to rule out other causes.
Specialist Consultation: Consult a pulmonologist for result interpretation. A rheumatologist referral is advised for systemic involvement.
Additional Supporting Tests: Chest imaging, calcium levels, or biopsy to confirm sarcoidosis or assess disease extent.
Test Limitations: False positives may occur with other granulomatous diseases. Results require clinical correlation.
References: ATS Sarcoidosis Guidelines, 2023; American Journal of Respiratory and Critical Care Medicine, Baughman RP, 2022.
